CL2018001236A1 - Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo. - Google Patents

Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo.

Info

Publication number
CL2018001236A1
CL2018001236A1 CL2018001236A CL2018001236A CL2018001236A1 CL 2018001236 A1 CL2018001236 A1 CL 2018001236A1 CL 2018001236 A CL2018001236 A CL 2018001236A CL 2018001236 A CL2018001236 A CL 2018001236A CL 2018001236 A1 CL2018001236 A1 CL 2018001236A1
Authority
CL
Chile
Prior art keywords
azaindolin
derivative
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
Prior art date
Application number
CL2018001236A
Other languages
English (en)
Inventor
Byeong-Seon Jeong
Jung-Ae Kim
Tae-Gyu Nam
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CL2018001236A1 publication Critical patent/CL2018001236A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona a un derivado de 7-azaindolin-2-ona o una sal farmacéuticamente aceptable del mismo, y el derivado de 7-azaindolin-2-ona o la sal farmacéuticamente aceptable del mismo se puede utilizar favorablemente como un material medicinal para inhibir el crecimiento de cáncer y metástasis de cáncer.
CL2018001236A 2015-11-12 2018-05-08 Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo. CL2018001236A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20150158695 2015-11-12

Publications (1)

Publication Number Publication Date
CL2018001236A1 true CL2018001236A1 (es) 2018-08-24

Family

ID=58695675

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001236A CL2018001236A1 (es) 2015-11-12 2018-05-08 Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo.

Country Status (18)

Country Link
US (1) US10544140B2 (es)
EP (1) EP3363799A4 (es)
JP (1) JP6661766B2 (es)
KR (1) KR102109869B1 (es)
CN (1) CN108368108B (es)
AU (1) AU2016353573B2 (es)
BR (1) BR112018009482A2 (es)
CA (1) CA3004595A1 (es)
CL (1) CL2018001236A1 (es)
CO (1) CO2018005367A2 (es)
EA (1) EA201891136A1 (es)
IL (1) IL259083A (es)
MA (1) MA42361A1 (es)
MX (1) MX2018005894A (es)
NZ (1) NZ742228A (es)
PH (1) PH12018500946A1 (es)
WO (1) WO2017082569A1 (es)
ZA (1) ZA201803722B (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AU5468499A (en) * 1998-08-04 2000-02-28 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
CA2395520A1 (en) * 1999-12-21 2001-06-28 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
US8829039B2 (en) * 2008-05-23 2014-09-09 Shanghai Institute Of Pharmaceutical Industry Dihydroindolinone derivatives
EP3604307A1 (en) * 2012-01-26 2020-02-05 Angion Biomedica Corp. Anti-fibrotic compounds and uses thereof
CN104884059B (zh) * 2012-11-30 2018-08-10 罗切斯特大学 用于hiv/aids治疗的混合谱系激酶抑制剂
US9187454B2 (en) 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
HK1220184A1 (zh) * 2013-03-13 2017-04-28 Boston Biomedical, Inc. 用於治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物
CN104876928B (zh) * 2015-05-07 2016-09-14 浙江司太立制药股份有限公司 7-氮杂吲哚啉-2-酮类化合物及其制备方法

Also Published As

Publication number Publication date
PH12018500946A1 (en) 2018-11-12
JP6661766B2 (ja) 2020-03-11
AU2016353573B2 (en) 2019-11-21
ZA201803722B (en) 2019-03-27
WO2017082569A1 (ko) 2017-05-18
EP3363799A4 (en) 2018-12-05
EP3363799A1 (en) 2018-08-22
US10544140B2 (en) 2020-01-28
BR112018009482A2 (pt) 2018-11-06
MX2018005894A (es) 2018-08-15
US20180370964A1 (en) 2018-12-27
AU2016353573A1 (en) 2018-05-24
CN108368108B (zh) 2021-09-21
CO2018005367A2 (es) 2018-06-12
IL259083A (en) 2018-06-28
JP2018533600A (ja) 2018-11-15
MA42361A1 (fr) 2018-09-28
KR102109869B1 (ko) 2020-05-13
KR20170056430A (ko) 2017-05-23
CA3004595A1 (en) 2017-05-18
NZ742228A (en) 2019-09-27
CN108368108A (zh) 2018-08-03
EA201891136A1 (ru) 2018-10-31

Similar Documents

Publication Publication Date Title
ZA202308496B (en) Pharmaceutical compositions of therapeutically active compounds
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
MX2017016149A (es) Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
ECSP17085443A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma
MX2017007699A (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX2017002737A (es) Farmaceutico que contiene inhibidor de transportador de fosfato dependiente de sodio.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
CO2018005367A2 (es) Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico
CL2017000026A1 (es) Formas de dosificación farmacéutica
MX383685B (es) Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia.
ZA201606135B (en) Pharmaceutical compositions of therapeutically active compounds
HK1233185A1 (en) Pharmaceutical compositions of therapeutically active compounds